| Literature DB >> 35443961 |
Anne M de Graaff1, Pim Cuijpers2, Ceren Acarturk3, Aemal Akhtar4, Mhd Salem Alkneme5, May Aoun6, Manar Awwad7, Ahmad Y Bawaneh7, Felicity L Brown6,8, Richard Bryant4, Sebastian Burchert5, Kenneth Carswell9, Annelieke Drogendijk10, Michelle Engels11, Daniela C Fuhr12, Pernille Hansen11, Edith van 't Hof9, Luana Giardinelli7, Mahmoud Hemmo13, Jonas M Hessling5, Zeynep Ilkkursun3, Mark J D Jordans6,8, Nikolai Kiselev13, Christine Knaevelsrud5, Gülsah Kurt3, Saara Martinmäki10, David McDaid14, Naser Morina13, Hadeel Naser7, A-La Park14, Monique C Pfaltz13,15, Bayard Roberts12, Matthis Schick13, Ulrich Schnyder13, Julia Spaaij13, Frederik Steen6, Karine Taha6, Ersin Uygun16, Peter Ventevogel17, Claire Whitney7, Anke B Witteveen2, Marit Sijbrandij2.
Abstract
INTRODUCTION: The World Health Organization's (WHO) scalable psychological interventions, such as Problem Management Plus (PM+) and Step-by-Step (SbS) are designed to be cost-effective non-specialist delivered interventions to reduce symptoms of common mental disorders, such as anxiety, depression and post-traumatic stress disorder (PTSD). The STRENGTHS consortium aims to evaluate the effectiveness, cost-effectiveness and implementation of the individual format of PM+ and its group version (gPM+), as well as of the digital SbS intervention among Syrian refugees in seven countries in Europe and the Middle East. This is a study protocol for a prospective individual participant data (IPD) meta-analysis to evaluate (1) overall effectiveness and cost-effectiveness and (2) treatment moderators of PM+, gPM+ and SbS with Syrian refugees. METHODS AND ANALYSIS: Five pilot randomised controlled trials (RCTs) and seven fully powered RCTs conducted within STRENGTHS will be combined into one IPD meta-analytic dataset. The RCTs include Syrian refugees of 18 years and above with elevated psychological distress (Kessler Psychological Distress Scale (K10>15)) and impaired daily functioning (WHO Disability Assessment Schedule 2.0 (WHODAS 2.0>16)). Participants are randomised into the intervention or care as usual control group, and complete follow-up assessments at 1-week, 3-month and 12-month follow-up. Primary outcomes are symptoms of depression and anxiety (25-item Hopkins Symptom Checklist). Secondary outcomes include daily functioning (WHODAS 2.0), PTSD symptoms (PTSD Checklist for DSM-5) and self-identified problems (PSYCHLOPS). We will conduct a one-stage IPD meta-analysis using linear mixed models. Quality of evidence will be assessed using the GRADE approach, and the economic evaluation approach will be assessed using the CHEC-list. ETHICS AND DISSEMINATION: Local ethical approval has been obtained for each RCT. This IPD meta-analysis does not require ethical approval. The results of this study will be published in international peer-reviewed journals. © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ.Entities:
Keywords: Anxiety disorders; Depression & mood disorders; MENTAL HEALTH
Mesh:
Year: 2022 PMID: 35443961 PMCID: PMC9021771 DOI: 10.1136/bmjopen-2021-058101
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 3.006
Trial descriptions
| Study site | Trial | Intervention | Setting | Inclusion criteria | Exclusion criteria | Preregistration trial | Trial dates* |
| Netherlands | Pilot | PM+ | Community | STRENGTHS criteria† | STRENGTHS criteria‡ | NTR: NL6665 | April 2018–March 2019 |
| RCT | PM+ | Community | STRENGTHS criteria† | STRENGTHS criteria‡; Current receipt of specialised psychological treatment | NTR: NL7552 | February 2019–ongoing | |
| Switzerland | Pilot | PM+ | Community | STRENGTHS criteria† | STRENGTHS criteria‡; Being under guardianship; Inability to follow study procedures | ClinicalTrials.gov: NCT03830008 | December 2018–March 2020 |
| RCT | PM+ | Community | STRENGTHS criteria† + Arabic-speaking refugees 18+yrs | STRENGTHS criteria‡; Being under guardianship; Inability to follow study procedures | ClinicalTrials.gov: NCT04574466 | February 2020–ongoing | |
| Turkey | Pilot | gPM+ | Community | STRENGTHS criteria† | STRENGTHS criteria‡ | ClinicalTrials.gov: NCT03567083 | September 2018–January 2019 |
| RCT | gPM+ | Community | STRENGTHS criteria† | STRENGTHS criteria‡ | ClinicalTrials.gov: NCT03960892 | August 2019–November 2021 | |
| Jordan | Pilot | gPM+ | Refugee camp | STRENGTHS criteria† + Having a child or dependent aged 10–16 years | STRENGTHS criteria‡ | ANZCTR: ACTRN12619000168156 | January–April 2019 |
| RCT | gPM+ | Refugee camp | STRENGTHS criteria† + Having a child or dependent aged 10–16 years | STRENGTHS criteria‡ | ANZCTR: ACTRN12619001386123 | August 2019–July 2020 | |
| Germany | Pilot | SbS | Digital | STRENGTHS criteria† | Signs of imminent suicide risk | DRKS: DRKS00017838 | December 2019–October 2020 |
| RCT | SbS | Digital | STRENGTHS criteria† | Signs of imminent suicide risk | DRKS: DRKS00022143 | August 2020–ongoing | |
| Sweden | RCT | SbS | Digital | STRENGTHS criteria† | Signs of imminent suicide risk | DRKS: DRKS00022144 | August 2020–ongoing |
| Egypt | RCT | SbS | Digital | STRENGTHS criteria† | Signs of imminent suicide risk | DRKS: DRKS00023505 | March 2021–ongoing |
*Recruitment to follow-up.
†STRENGTHS inclusion criteria = Arabic-speaking Syrian refugees 18+years + K10>15 + WHODAS 2.0>16.
‡STRENGTHS exclusion criteria = Signs of imminent suicide risk, acute medical conditions, expressed acute needs or protection risks, and/or Indications of severe mental disorders.
ANZCTR, Australian New Zealand Clinical Trials Registry; gPM+, group PM+; K10, Kessler Psychological Distress Scale; NTR, Netherlands Trial Register; pilot, pilot RCT; PM+, Problem Management Plus; RCT, fully-powered RCT; SbS, step-by-step; STRENGTHS, Syrian REfuGees MeNTal HealTH Care Systems; WHODAS 2.0, WHO Disability Assessment Schedule 2.0.